NASDAQ:AEZS

Aeterna Zentaris - AEZS Stock Forecast, Price & News

$3.80

+0.11 (+2.98%)

(As of 09/27/2022 12:00 AM ET)

Add

Compare

Today's Range: $3.70
▼
$3.84
50-Day Range: $3.69
▼
$5.57
52-Week Range: $3.69
▼
$24.38

Volume: 13,819 shs
Average Volume: 45,502 shs
Market Capitalization: $18.45 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $37.50

Aeterna Zentaris MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 886.8% Upside
$37.50 Price Target
Short Interest: Healthy
2.88% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.89
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($2.83) to ($3.14) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.22 out of 5 stars

Medical Sector

533rd out of 1,071 stocks

Pharmaceutical Preparations Industry

248th out of 531 stocks

3.5

Analyst's Opinion

Consensus Rating
Aeterna Zentaris has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $37.50, Aeterna Zentaris has a forecasted upside of 886.8% from its current price of $3.80.
Amount of Analyst Coverage
Aeterna Zentaris has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
2.88% of the float of Aeterna Zentaris has been sold short.
Short Interest Ratio / Days to Cover
Aeterna Zentaris has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Aeterna Zentaris has recently decreased by 9.00%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Aeterna Zentaris does not currently pay a dividend.
Dividend Growth
Aeterna Zentaris does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AEZS.

3.3

News and Social Media Coverage

News Sentiment
Aeterna Zentaris has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Aeterna Zentaris this week, compared to 0 articles on an average week.
Search Interest
Only 1 people have searched for AEZS on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Aeterna Zentaris to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aeterna Zentaris insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 30.96% of the stock of Aeterna Zentaris is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Aeterna Zentaris are expected to decrease in the coming year, from ($2.83) to ($3.14) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Aeterna Zentaris is -1.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Aeterna Zentaris is -1.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Aeterna Zentaris has a P/B Ratio of 0.35. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Aeterna Zentaris (NASDAQ:AEZS) Stock

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.

Receive AEZS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aeterna Zentaris and its competitors with MarketBeat's FREE daily newsletter.

AEZS Stock News Headlines

August 29, 2022 | finance.yahoo.com

Aeterna Zentaris Set to Regain Full Rights to Macrilen™ (Macimorelin) in U.S. and Canada from Novo Nordisk

July 19, 2022 | finanznachrichten.de

Aeterna Zentaris Inc: Aeterna Zentaris Announces Effective Date of Share Consolidation

June 9, 2022 | finance.yahoo.com

Aeterna Zentaris to Present at the JMP Securities Life Sciences Conference

May 25, 2022 | seekingalpha.com

Aeterna Zentaris licensing partner Consilient launches growth hormone deficiency test in Europe

May 11, 2022 | investing.com

Aeterna Zentaris Reports Q1 Net Loss of $2.6M, Provides Business Outlook

May 11, 2022 | finance.yahoo.com

Aeterna Zentaris Reports First Quarter 2022 Financial Results and Provides Business Outlook

April 19, 2022 | seekingalpha.com

Aeterna Zentaris gets European patent related to macimorelin to detect growth hormone deficiency

April 19, 2022 | finance.yahoo.com

Aeterna Zentaris Secures New European Patent Related to Use of Macimorelin for the Diagnosis of Growth Hormone Deficiency in Adults

April 11, 2022 | finance.yahoo.com

Aeterna Zentaris Abstract Accepted for Presentation at 13th International Congress on Autoimmunity

March 29, 2022 | finance.yahoo.com

Aeterna Zentaris Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Outlook

March 23, 2022 | morningstar.com

Aeterna Zentaris Provides Update on Ongoing Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency | Morningstar

March 21, 2022 | finance.yahoo.com

Aeterna Zentaris Says Enrollment In Growth Hormone Deficiency Trial To Continue Into 2023

March 17, 2022 | finance.yahoo.com

Synlogic, Inc. (SYBX) Reports Q4 Loss, Misses Revenue Estimates

March 10, 2022 | seekingalpha.com

Aeterna Zentaris expands research program for COVID-19/Chlamydia vaccines

March 10, 2022 | finance.yahoo.com

Aeterna Zentaris Announces Expansion of Research Program with Julius-Maximilians-University Wuerzburg Aiming to Accelerate Development of Vaccine Programs

January 20, 2022 | finance.yahoo.com

Aeterna Zentaris to Present at the Virtual Investor 2022 Top Picks Conference

December 25, 2021 | nz.finance.yahoo.com

Companies Like Aeterna Zentaris (TSE:AEZS) Can Afford To Invest In Growth

December 24, 2021 | seekingalpha.com

Aeterna Zentaris names new finance chief

December 24, 2021 | seekingalpha.com

Aeterna Zentaris names new finance chief

November 4, 2021 | finance.yahoo.com

Aeterna Zentaris Reports Third Quarter 2021 Financial Results and Provides Pipeline Program Updates

October 28, 2021 | sg.finance.yahoo.com

Aeterna Zentaris Announces Results of Annual and Special Shareholders’ Meeting

September 26, 2021 | finance.yahoo.com

Aeterna Zentaris (TSE:AEZS) shareholders have endured a 82% loss from investing in the stock five years ago

September 8, 2021 | finance.yahoo.com

Aeterna Zentaris to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

August 4, 2021 | finance.yahoo.com

Aeterna Zentaris Reports Second Quarter 2021 Financial Results and Provides Pipeline Program Updates

July 16, 2021 | uk.finance.yahoo.com

AEZS Jul 2021 3.000 put

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive AEZS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aeterna Zentaris and its competitors with MarketBeat's FREE daily newsletter.

AEZS Company Calendar

Last Earnings: 11/04/2021
Today: 9/27/2022
Next Earnings (Estimated): 11/03/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AEZS
CUSIP: N/A
CIK: 1113423
Web: www.zentaris.com
Phone: (843) 900-3223
Fax: 418-948-9191
Employees: 11
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $37.50
High Stock Price Forecast: $37.50
Low Stock Price Forecast: $37.50
Forecasted Upside/Downside: +886.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.12)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-8,370,000.00
Net Margins: -252.34%
Pretax Margin: -408.76%
Return on Equity: -20.78%
Return on Assets: -14.76%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 9.86
Quick Ratio: 9.82

Sales & Book Value

Annual Sales: $5.26 million
Price / Sales: 3.51
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $10.91 per share
Price / Book: 0.35

Miscellaneous

Outstanding Shares: 4,856,000
Free Float: N/A
Market Cap: $18.45 million
Optionable: Optionable
Beta: 1.34

Social Links

Key Executives

Dr. Klaus Paulini Ph.D.
Pres, CEO & Exec. Director

Dr. Nicola Ammer M.D.
Chief Medical Officer & Sr. VP of Clinical Devel.

Dr. Matthias Gerlach
Sr. VP Manufacturing & Supply Chain

Mr. Giuliano La Fratta
Sr. VP of Fin. & CFO

Dr. Michael Teifel
Sr. VP of Non-Clinical Devel. & Chief Scientific Officer

Dr. Eckhard G. Guenther Ph.D.
Sr. VP of Bus. Devel. & Alliance Management and MD of AEZS Germany

Ms. Amélie Métivier
Assistant Sec.

Key Competitors

View All Competitors

Insiders & Institutions

Group One Trading L.P.
Sold 100 shares on 8/11/2022
Ownership: 0.000%

View All Insider Transactions
View All Institutional Transactions

AEZS Stock - Frequently Asked Questions

Should I buy or sell Aeterna Zentaris stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aeterna Zentaris in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" AEZS shares.
View AEZS analyst ratings or view top-rated stocks.
What is Aeterna Zentaris' stock price forecast for 2022?: 1 brokers have issued twelve-month price targets for Aeterna Zentaris' stock. Their AEZS share price forecasts range from $37.50 to $37.50. On average, they expect the company's share price to reach $37.50 in the next year. This suggests a possible upside of 886.8% from the stock's current price.
View analysts price targets for AEZS or view top-rated stocks among Wall Street analysts.
How have AEZS shares performed in 2022?: Aeterna Zentaris' stock was trading at $8.8750 at the start of the year. Since then, AEZS stock has decreased by 57.2% and is now trading at $3.80.
View the best growth stocks for 2022 here.
When is Aeterna Zentaris' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our AEZS earnings forecast.
How were Aeterna Zentaris' earnings last quarter?: Aeterna Zentaris Inc. (NASDAQ:AEZS) released its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.50) by $0.25. The biopharmaceutical company had revenue of $0.60 million for the quarter, compared to analyst estimates of $0.60 million. Aeterna Zentaris had a negative net margin of 252.34% and a negative trailing twelve-month return on equity of 20.78%.
When did Aeterna Zentaris' stock split?: Aeterna Zentaris's stock reverse split on Thursday, July 21st 2022. The 1-25 reverse split was announced on Thursday, July 21st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Aeterna Zentaris own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Aeterna Zentaris investors own include Zosano Pharma (ZSAN), Pennsylvania Real Estate Investment Trust (PEI), CBL & Associates Properties (CBL), Gran Tierra Energy (GTE), CNBX Pharmaceuticals (CNBX), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Novan (NOVN) and Washington Prime Group (WPG).
What is Aeterna Zentaris' stock symbol?: Aeterna Zentaris trades on the NASDAQ under the ticker symbol "AEZS."
Who are Aeterna Zentaris' major shareholders?: Aeterna Zentaris' stock is owned by many different retail and institutional investors. Top institutional investors include Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%).
How do I buy shares of Aeterna Zentaris?: Shares of AEZS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Aeterna Zentaris' stock price today?: One share of AEZS stock can currently be purchased for approximately $3.80.
How much money does Aeterna Zentaris make?: Aeterna Zentaris (NASDAQ:AEZS) has a market capitalization of $18.45 million and generates $5.26 million in revenue each year. The biopharmaceutical company earns $-8,370,000.00 in net income (profit) each year or ($2.12) on an earnings per share basis.
How can I contact Aeterna Zentaris?: Aeterna Zentaris' mailing address is 315 Sigma Drive South Carolina, Summerville SC, 29486. The official website for the company is www.zentaris.com. The biopharmaceutical company can be reached via phone at (843) 900-3223, via email at ir@aezsinc.com, or via fax at 418-948-9191.

This page (NASDAQ:AEZS) was last updated on 9/28/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Aeterna Zentaris - AEZS Stock Forecast, Price & News

Aeterna Zentaris MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows